Inflammatory abnormality of the skin (HP:0011123)
The presence of inflammation of the skin. That is, an abnormality of the skin resulting from the local accumulation of fluid, plasma proteins, and leukocytes.
Synonyms: Inflammatory abnormality of the skin, Skin inflammation, Abnormal tendency to infections of the skin, Dermatitis, Inflammatory skin disease
Cross References: MP:0004947, MSH:D003872, SNOMEDCT_US:703938007, UMLS:C0011603, UMLS:C3875321
KEGG Pathway
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | Primary immunodeficiency | 6.488e-15 | 1.687e-13 | 935.53 | 30562.71 |
| 2 | Th1 and Th2 cell differentiation | 4.565e-10 | 5.934e-9 | 228.77 | 4920.26 |
| 3 | T cell receptor signaling pathway | 8.515e-10 | 6.394e-9 | 200.92 | 4196.00 |
| 4 | Th17 cell differentiation | 9.837e-10 | 6.394e-9 | 194.98 | 4043.83 |
| 5 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 7.537e-8 | 3.919e-7 | 156.12 | 2560.47 |
GO: Biological Process
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | positive thymic T cell selection (GO:0045059) | 1.574e-13 | 1.401e-11 | 13326.00 | 392846.55 |
| 2 | antigen receptor-mediated signaling pathway (GO:0050851) | 6.059e-13 | 2.696e-11 | 259.71 | 7306.12 |
| 3 | V(D)J recombination (GO:0033151) | 0.00001235 | 0.00009988 | 555.03 | 6273.06 |
| 4 | lymphocyte differentiation (GO:0030098) | 2.870e-10 | 6.785e-9 | 252.04 | 5537.62 |
| 5 | B cell activation (GO:0042113) | 3.049e-10 | 6.785e-9 | 248.88 | 5453.09 |
GO: Molecular Function
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | signaling receptor complex adaptor activity (GO:0030159) | 0.0001651 | 0.005613 | 134.82 | 1174.13 |
| 2 | endodeoxyribonuclease activity (GO:0004520) | 0.009957 | 0.07074 | 116.79 | 538.34 |
| 3 | phosphatidylinositol-3,5-bisphosphate binding (GO:0080025) | 0.01194 | 0.07074 | 96.46 | 427.12 |
| 4 | phosphatidylinositol-3,4-bisphosphate binding (GO:0043325) | 0.01293 | 0.07074 | 88.73 | 385.85 |
| 5 | phosphatidylinositol-3,4,5-trisphosphate binding (GO:0005547) | 0.01737 | 0.07074 | 65.22 | 264.33 |
GO: Cellular Component
| Index | Name | P-value | Adjusted p-value | Odds Ratio | Combined score |
| 1 | alpha-beta T cell receptor complex (GO:0042105) | 1.799e-9 | 1.259e-8 | 2855.29 | 57494.92 |
| 2 | T cell receptor complex (GO:0042101) | 1.556e-11 | 2.179e-10 | 1665.17 | 41439.58 |
| 3 | clathrin-coated endocytic vesicle (GO:0045334) | 0.000008701 | 0.00004060 | 104.05 | 1212.39 |
| 4 | clathrin-coated endocytic vesicle membrane (GO:0030669) | 0.0005185 | 0.001452 | 74.34 | 562.35 |
| 5 | clathrin-coated vesicle membrane (GO:0030665) | 0.0008802 | 0.002054 | 56.54 | 397.78 |
Hub genes predicted as biomarkers & predicted FDA approved drugs
| Hub Genes (ranked) | FDA-Approved Drugs |
| ZAP70 | – |
| CD3E | MUROMMONAB-CD3, CATUMAXOMAB, BLINATUMOMAB |
| CTLA4 | IPILIMUMAB, ABATACEPT |
| CD3D | MUROMMONAB-CD3, CATUMAXOMAB, BLINATUMOMAB |
| CD3G | MUROMMONAB-CD3, CATUMAXOMAB, BLINATUMOMAB |
| RAG1 | – |
| CD79B | POLATUZUMAB VEDOTIN |
| RAG2 | – |
| CD79A | – |
| IL2RA | BASILIXIMAB, DACLIZUMAB, ALDESLEUKIN, DENILEUKIN DIFTITOX, CETIRIZINE |
